Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Programs for Autism: Red Flags and Evidence
Transcript
- 0:00SPEAKER_01: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_00: It is great to be here.
- 0:03SPEAKER_01: So if you break an arm, an X-ray gives you a very clean, binary answer.
- 0:08SPEAKER_01: It is broken or it is not broken.
- 0:10SPEAKER_01: Yeah.
- 0:11SPEAKER_01: You look at the scan and you see the jagged white line.
- 0:14SPEAKER_01: The doctor points to the problem, and then you just fix it.
- 0:17SPEAKER_00: It is very straightforward.
- 0:19SPEAKER_01: But diagnosing and treating neurodevelopmental conditions like autism is a completely different universe.
- 0:25SPEAKER_01: That X-ray machine is totally useless here.
- 0:28SPEAKER_00: Absolutely.
- 0:29SPEAKER_00: The diagnostic landscape is murky.
- 0:32SPEAKER_01: And into those muddy waters steps a massive, highly lucrative industry.
- 0:36SPEAKER_01: So today we are taking a deep dive into stem cell programs that are marketed directly to parents of children with autism.
- 0:42SPEAKER_00: And our mission for this deep dive is to really unpack the evidence.
- 0:46SPEAKER_00: We need to identify the red flags and understand the science behind these programs without any of the marketing hype.
- 0:53SPEAKER_01: Yeah, we have to establish a grounded, evidence-based tone from the very first minute.
- 0:57SPEAKER_01: We are examining experimental research today.
- 1:00SPEAKER_00: I agree completely.
- 1:01SPEAKER_00: We will never refer to stem cell therapy as a cure, and we cannot promise any results to anyone listening.
- 1:08SPEAKER_01: Most importantly, exploring these options should never replace a child's current therapies or a doctor's medical advice.
- 1:14SPEAKER_01: We have to view these interventions through a lens of strict scientific scrutiny.
- 1:18SPEAKER_00: Definitely.
- 1:19SPEAKER_01: So let us unpack the first major piece of this puzzle.
- 1:22SPEAKER_01: We are talking about paid stem cell treatment packages that are marketed specifically for children with autism.
- 1:29SPEAKER_00: Yes.
- 1:29SPEAKER_00: And these packages generally involve providing children with cells derived from umbilical cord blood or umbilical cord tissue.
- 1:37SPEAKER_01: According to a 2022 review in Frontiers and Pediatrics, these programs differ widely in their injection routes and the doses given to the children.
- 1:47SPEAKER_00: That is a big issue.
- 1:48SPEAKER_00: Some clinics use intravenous drips, and others use completely different methods.
- 1:53SPEAKER_00: The cell counts can vary by the millions.
- 1:56SPEAKER_01: The differences in those paid packages are significant.
- 1:59SPEAKER_01: But to understand the market, we really have to look at the underlying hope of driving parents to these packages in the first place.
- 2:05SPEAKER_00: Aaron Powell The motivation often stems from a very specific biological theory.
- 2:09SPEAKER_00: Some researchers have linked autism with immune activity and inflammation in the brain.
- 2:15SPEAKER_01: So the theory suggests that certain immune cells are overactive.
- 2:20SPEAKER_00: Yes.
- 2:20SPEAKER_00: They create an inflammatory environment.
- 2:22SPEAKER_00: And that affects how brain networks develop and communicate.
- 2:25SPEAKER_01: So providers of these paid packages hope that by introducing new unspecialized cells, they will ease autism spectrum disorder symptoms, basically by calming that inflammation.
- 2:36SPEAKER_00: They view the stem cells as cellular paramedics.
- 2:41SPEAKER_00: Paramedics that can send out chemical signals to quiet the immune response.
- 2:53SPEAKER_00: I see what you mean.
- 2:54SPEAKER_01: Consider a massive fire burning inside a house.
- 2:57SPEAKER_01: The fire represents the inflammation in the brain.
- 2:59SPEAKER_01: If you bring in a fire hose and flood the living room, you put out that fire.
- 3:04SPEAKER_00: Aaron Powell You have successfully stopped the act of destruction.
- 3:06SPEAKER_01: Aaron Powell But putting out the fire does not magically rebuild the drywall.
- 3:10SPEAKER_01: It does not fix the plumbing or restore the structural integrity of the house.
- 3:14SPEAKER_00: Aaron Ross Powell You still need carpenters and electricians for that.
- 3:17SPEAKER_01: Trevor Burrus Yes.
- 3:17SPEAKER_01: Calming the brain's environment does not necessarily weave new neural pathways together.
- 3:22SPEAKER_00: Aaron Powell That analogy captures the scientific hesitation perfectly.
- 3:26SPEAKER_00: A 2026 journal review specifically cautions against making that leap, the leap from calming inflammation to expecting cognitive changes.
- 3:33SPEAKER_01: Aaron Powell Because finding a link does not mean causation.
- 3:36SPEAKER_00: Yes.
- 3:37SPEAKER_00: Finding an immune link does not show that the immune system actually causes autism.
- 3:41SPEAKER_00: It could be a byproduct of other underlying factors.
- 3:49SPEAKER_01: Calming the cellular environment, you know, putting out the fire, does not rebuild the neural architecture in the way families might be hoping for.
- 3:57SPEAKER_00: So to understand that these packages work at all, we first need to look under the microscope.
- 4:02SPEAKER_00: We have to look at what is actually being injected into the body.
- 4:05SPEAKER_01: Aaron Powell We need to know what physical materials we are dealing with here.
- 4:08SPEAKER_01: There are a few different types of stem cells that autism programs use, and they differ significantly in what they contain.
- 4:15SPEAKER_00: Aaron Powell A 2026 review breaks down the three main categories found in autism research.
- 4:20SPEAKER_00: The first category is cord blood cells.
- 4:23SPEAKER_01: This is the blood left in the umbilical cord and placenta after a baby is born.
- 4:27SPEAKER_00: Yes.
- 4:27SPEAKER_00: This blood contains a very diverse, rich mix of cells, including hemopoietic cells, which create blood, and various immune cells.
- 4:36SPEAKER_01: And the second category is mesenchymal stem cells.
- 4:39SPEAKER_01: These are usually derived from umbilical cord tissue, specifically a gelatinous substance inside the cord.
- 4:45SPEAKER_00: In laboratory studies, these specific cells have been shown to release anti-inflammatory signals when they're placed in a petri dish, at least.
- 4:53SPEAKER_01: The third category is bone marrow cells.
- 4:56SPEAKER_01: These can be harvested directly from the marrow of the child themselves, in a surgical procedure, or they can be sourced from a healthy donor.
- 5:03SPEAKER_00: We also have to look at the regulatory reality surrounding these cells because it is incredibly strict.
- 5:09SPEAKER_01: In 2020, the United States Food and Drug Administration stated firmly that it had approved no stem cell product to treat autism.
- 5:17SPEAKER_00: The FDA issued an alert, noting that the only approved stem cell products are blood-forming cells, cells derived from cord blood.
- 5:25SPEAKER_01: And doctors are only permitted to use those approved products for serious disorders that affect blood production, like certain cancers or immune system deficiencies.
- 5:34SPEAKER_00: The regulatory agencies do not view these cells as a generalized treatment for neurological conditions.
- 5:40SPEAKER_00: And the 2026 review adds another layer of scientific reality to this whole discussion.
- 5:44SPEAKER_01: It reports that no clinical study has shown one cell source to work better than another for autism.
- 5:50SPEAKER_00: Aaron Powell Despite what a clinic's marketing brochure might claim, the science has simply not crowned a superior cell type or a superior delivery method for this application.
- 5:59SPEAKER_01: Aaron Powell I think we should look at a real-world example of how these providers operate internationally to ground this.
- 6:05SPEAKER_01: Take Cyrona Cell, for instance.
- 6:07SPEAKER_00: They are a regenerative medicine center based in Cybergyo, Malaysia.
- 6:12SPEAKER_01: Aaron Ross Powell They arrange treatments for patients at partner facilities in Kuala Lumpur, and they frequently speak with international patients.
- 6:19SPEAKER_00: Aaron Powell This includes families traveling all the way from Australia and the Middle East to seek these services.
- 6:24SPEAKER_01: According to Cyrona Cell's own statement, the cells they use are Wharton's jelly-derived mesenchymal stem cells, or WJMSCs for short, taken from umbilical cord tissue.
- 6:36SPEAKER_00: Wharton's jelly is that protective gelatinous tissue we just mentioned inside the umbilical cord.
- 6:41SPEAKER_01: We must be incredibly clear about the scientific literature here, though.
- 6:45SPEAKER_01: The research and the clinical trials cited in today's deep dive did not test Saronacell's specific treatment.
- 6:51SPEAKER_00: Yes, and they did not test SORONOCEL's specific cell batches.
- 6:55SPEAKER_00: The studies we are looking at evaluate the general, broad categories of cells we just discussed, not any one company's proprietary process.
- 7:04SPEAKER_01: Now that you know what physical materials are being used and how clinics source them, we have to ask what actually happens.
- 7:11SPEAKER_01: What happens when these specific cells are put to the test in formal clinical trials?
- 7:16SPEAKER_00: Let us look at the chronological progression of the data, starting with a heavily discussed 2017 Duke University study that generated a lot of headlines.
- 7:25SPEAKER_01: The 2017 Duke study was an early exploration involving 25 children.
- 7:30SPEAKER_00: These children received intravenous infusions of their own cord blood, meaning blood that had been banked by their parents at birth.
- 7:37SPEAKER_01: The researchers looked at a variety of metrics, including parent reports, clinician ratings, and eye tracking tests designed to measure attention.
- 7:45SPEAKER_00: The study found that the children showed better scores on several of these metrics at the six-month mark and the 12-month mark following the infusion.
- 7:54SPEAKER_01: I have to jump in here.
- 7:55SPEAKER_00: Okay.
- 7:56SPEAKER_01: Because there is a massive fundamental flaw in that 2017 study design, and it often gets glossed over in marketing materials.
- 8:03SPEAKER_00: The study had absolutely no comparison group.
- 8:06SPEAKER_01: It had no placebo group.
- 8:07SPEAKER_01: Imagine you decide to wear a lucky pair of socks on a day you have to take a very difficult licensing exam.
- 8:13SPEAKER_01: Okay.
- 8:13SPEAKER_01: You get a perfect score, and you happen to be wearing the socks.
- 8:17SPEAKER_01: If you run a study without a comparison group, it is like assuming the socks took the test for you.
- 8:23SPEAKER_00: Because without a group of people taking the identical test without the lucky socks, you cannot prove the socks caused the good grade.
- 8:30SPEAKER_01: Yes.
- 8:31SPEAKER_01: Without a comparison group in this 2017 study, researchers cannot definitively show that the stem cells actually caused the positive developmental changes.
- 8:40SPEAKER_00: That is the ultimate limitation of uncontrolled studies in medicine.
- 8:44SPEAKER_00: Children develop and mature over a 12-month period regardless of medical interventions, especially if they're receiving standard educational therapies at the same time.
- 8:53SPEAKER_01: The authors of the 2017 study were very transparent about this limitation.
- 8:57SPEAKER_01: They acknowledged that they designed the study primarily to test baseline safety.
- 9:02SPEAKER_00: And to figure out how to accurately measure outcomes for future better design trials.
- 9:06SPEAKER_00: Which brings us to the pivotal 2020 trial.
- 9:10SPEAKER_01: Researchers designed this much larger trial specifically to fix the flaw we just described.
- 9:15SPEAKER_01: They tested 180 children.
- 9:17SPEAKER_00: 56 children received their own cord blood, 63 received donor cord blood, and 61 children received a placebo, which was just a harmless inactive dummy infusion.
- 9:29SPEAKER_01: This is where the physical execution of the science is fascinating.
- 9:32SPEAKER_01: It is a double-blind structure, which is the gold standard for finding the truth in medicine.
- 9:36SPEAKER_00: Aaron Powell The IV bag is masked, the administering nurse does not know if the bag holds stem cells or saline.
- 9:43SPEAKER_01: The parents sitting in the room do not know.
- 9:45SPEAKER_01: And six months later, the doctor evaluating the child's behavior does not know.
- 9:49SPEAKER_01: It entirely removes human bias from the equation.
- 9:52SPEAKER_00: So what did the data show when they unblinded the results?
- 9:56SPEAKER_01: Aaron Powell The results were highly sobering for the commercial industry.
- 9:59SPEAKER_01: When they stripped away the bias, researchers found no overall gain in social skills or autism symptoms at the six-month mark.
- 10:07SPEAKER_00: The cord blood infusion simply did not improve social skills any more than the dummy placebo did.
- 10:13SPEAKER_01: There was one very specific doctor-rated scale where children without intellectual disability given donor blood showed a slight improvement.
- 10:21SPEAKER_00: But the authors explicitly noted that statistical chance could easily explain that small gap.
- 10:27SPEAKER_00: Overall, the rigorous trial found no overall clinical benefit.
- 10:31SPEAKER_01: So if the gold standard 2020 trial showed no overall benefit, why do some clinics still point to massive data sets claiming there is proof it works?
- 10:42SPEAKER_00: They usually do it by using pooled reviews.
- 10:44SPEAKER_00: They take the data from multiple smaller studies and combine them to look for larger trends.
- 10:50SPEAKER_01: But combining studies with different standards can create incredibly muddy, confusing results.
- 10:56SPEAKER_00: A 2022 review published in Frontiers and Pediatrics is a perfect example of this.
- 11:01SPEAKER_00: They pooled five different stem cell studies, comparing children who received cells with those who did not.
- 11:07SPEAKER_01: The results were remarkably mixed.
- 11:09SPEAKER_01: They showed lower scores on one specific autism rating scale for the stem cell group.
- 11:14SPEAKER_00: However, when looking at a different doctor-rated scale, 62% of the stem cell group improved.
- 11:20SPEAKER_00: But 60% of the comparison group also improved.
- 11:25SPEAKER_01: A 62% improvement compared to a 60% improvement is essentially a tied race.
- 11:30SPEAKER_01: It certainly does not point to a massive life-altering breakthrough caused exclusively by the cells.
- 11:36SPEAKER_00: Then we have a 2026 conference abstract published in European Psychiatry that pooled 22 different studies.
- 11:44SPEAKER_00: This abstract claimed a very large average gain for the children receiving treatments.
- 11:49SPEAKER_01: But when you look at the underlying data, the methodology was heavily flawed.
- 11:53SPEAKER_00: The researchers included studies where the families knew they were receiving the treatment, which introduces massive expectation bias.
- 12:01SPEAKER_01: Out of those 22 pooled studies, only three actually used a placebo for a clean comparison.
- 12:06SPEAKER_01: The vast majority of the data was uncontrolled.
- 12:09SPEAKER_00: If the benefits are this blurry and the data is this conflicting, you need to know what the physical risks are.
- 12:16SPEAKER_00: We cannot talk about potential behavioral gains without looking very closely at potential biological harms.
- 12:22SPEAKER_01: Especially when injecting living tissue.
- 12:35SPEAKER_00: There were no catastrophic immediate reactions.
- 12:38SPEAKER_01: However, the follow-up periods for these studies were severely limited.
- 12:42SPEAKER_01: The 2017 study only followed the children for 12 months, and the 2020 trial only followed them for six months.
- 12:49SPEAKER_00: A six to twelve month observation window is incredibly short.
- 12:53SPEAKER_00: When we are talking about injecting living biological material into the bloodstream of a young child, the long-term effects remain entirely unknown.
- 13:02SPEAKER_00: These are transplanted living cells.
- 13:04SPEAKER_00: They may stay in the child's body for years, integrating into tissues.
- 13:08SPEAKER_01: And we simply have no data on what happens a decade down the line.
- 13:12SPEAKER_01: The scientific community is actively investigating those unknowns currently.
- 13:16SPEAKER_00: A 2026 review published a very crucial, tangible finding regarding immune reactions.
- 13:22SPEAKER_00: The researchers found new antibodies against donor cells in five of the 12 children who had received donor cord tissue cells.
- 13:29SPEAKER_00: Let us break down the mechanics of that.
- 13:31SPEAKER_00: What is actually happening in the child's body when these new antibodies form against the donor cells?
- 13:37SPEAKER_01: Well, the donor cells carry surface proteins.
- 13:40SPEAKER_01: When they enter the bloodstream, the child's immune system acts like a security scanner.
- 13:44SPEAKER_00: It reads those proteins, identifies the cells as foreign invaders, and manufactures antibodies.
- 13:50SPEAKER_01: These antibodies act like chemical tracking tags that lock onto the donor cells, marking them for destruction by the body's white blood cells.
- 13:58SPEAKER_00: It means the child immune system mounted a complex biological response to the treatment.
- 14:03SPEAKER_01: While none of the children in that specific review showed outward negative health symptoms from this reaction during the study window, the finding is highly significant.
- 14:12SPEAKER_00: It proves that researchers are still actively mapping the safety profile of donor cells.
- 14:17SPEAKER_00: And it shows that a child's body is reacting to the treatment in intricate ways we do not fully comprehend yet.
- 14:23SPEAKER_01: With unknown long-term physical risks on the table and clear evidence of the body mounting internal immune responses, navigating this market is incredibly difficult.
- 14:32SPEAKER_00: You have clinics running highly persuasive marketing campaigns selling unproven hope.
- 14:38SPEAKER_00: How can parents safely navigate this?
- 14:40SPEAKER_01: The International Society for Stem Cell Research, known as the ISSCR, recognizes how predatory this landscape can be.
- 14:48SPEAKER_00: In 2024, they published a comprehensive patient guide to help families spot the warning signs of weak or exploitative programs.
- 14:55SPEAKER_00: They outlined several critical red flags.
- 14:58SPEAKER_01: The first major red flag is when a clinic uses parent stories, videos, or testimonials as their primary scientific proof that the treatment works.
- 15:06SPEAKER_00: I can easily see why anecdotes are dangerous.
- 15:09SPEAKER_00: If a parent posts a video saying their child started speaking in full sentences three months after the infusion, it is very hard not to believe the infusion caused the speech.
- 15:18SPEAKER_01: But a child's brain is naturally maturing anyway.
- 15:21SPEAKER_01: Or maybe that child was undergoing intensive speech therapy for hours a week at the exact same time.
- 15:27SPEAKER_00: Without a controlled trial, you cannot isolate the variables.
- 15:30SPEAKER_00: So it is scientifically impossible to attribute that new skill exclusively to the stem cells.
- 15:36SPEAKER_01: Anecdotes pull out our emotions, but they are not clinical evidence.
- 15:40SPEAKER_00: Another massive red flag, the ISSCR points out, is charging fees to join a clinical trial.
- 15:47SPEAKER_01: Legitimate, scientifically rigorous clinical trials are funded by grants or institutions.
- 15:52SPEAKER_01: They do not normally charge the participants a fee to be involved.
- 15:56SPEAKER_00: If a clinic asks for thousands of dollars to enroll your child in their study, you should be highly suspicious.
- 16:02SPEAKER_01: I would imagine hidden costs are a nightmare in this space, too.
- 16:05SPEAKER_01: You might pay for the initial infusion up front, but what happens if the child has an adverse biological reaction?
- 16:12SPEAKER_00: The clinic probably leaves the family entirely financially irresponsible for the emergency room bill and any subsequent intensive care.
- 16:20SPEAKER_01: The ISS CR guide highlights hidden costs as a major warning sign.
- 16:24SPEAKER_01: Clinics often wash their hands of the patient once the infusion is complete.
- 16:28SPEAKER_00: Unclear cell sources are another definitive warning sign.
- 16:32SPEAKER_01: If a clinic cannot provide a clear, transparent, written record of exactly where the cells came from, and how they were screened for infectious diseases, and how they were processed in the lab, parents should walk away immediately.
- 16:45SPEAKER_00: Finally, any clinic claiming that a treatment carries absolutely no risk is flying a massive red flag.
- 16:52SPEAKER_00: Every medical intervention, even a simple aspirin, carries some degree of risk.
- 16:56SPEAKER_01: If a parent is looking at a glossy brochure and wants to independently verify the claims a clinic is making, what specific documents should they demand to see to check the evidence?
- 17:07SPEAKER_00: The ISSCR provides a very strict, unemotional checklist for parents.
- 17:12SPEAKER_00: First, parents must ask for published, peer-reviewed studies that test the exact same cell product, the exact same dose that the clinic is offering.
- 17:21SPEAKER_01: They should not accept a study on general stem cells.
- 17:24SPEAKER_01: They need studies on the specific proprietary product the clinic uses.
- 17:29SPEAKER_00: Second, parents must ask for written treatment protocols.
- 17:32SPEAKER_00: These protocols serve as the strict operating manual for the procedure, detailing every step.
- 17:37SPEAKER_01: Third, families must receive a signed consent form that explicitly lists all known physical risks and states clearly in writing that the treatment is scientifically unproven.
- 17:48SPEAKER_00: Fourth, parents should seek an independent doctor's view.
- 17:51SPEAKER_00: They need a physician completely unaffiliated with the clinic who has no financial stake in the decision to review the child's full medical history and the clinic's proposal.
- 18:00SPEAKER_01: I know a lot of these clinics point to their listing on public clinical trial databases as proof that they are legitimate, government-approved operations.
- 18:08SPEAKER_00: The ISSCR guide tackles that misconception directly.
- 18:12SPEAKER_00: Just being listed in a public registry database, like clinicaltrials.gov is not proof that a treatment actually works.
- 18:19SPEAKER_01: It is also not proof that the clinic has strict regulatory oversight or ethical approval.
- 18:24SPEAKER_01: It is merely a database entry.
- 18:26SPEAKER_01: Anyone can submit a form.
- 18:28SPEAKER_00: Furthermore, because these products contain living biological cells, the manufacturing process is incredibly volatile.
- 18:35SPEAKER_00: The makers must test every single batch for consistency, purity, and safety, which many commercial clinics fail to do comprehensively.
- 18:44SPEAKER_01: Since stem cell programs remain highly experimental, vastly unproven, and carry unmapped long-term risks, what should families be doing at this moment?
- 18:53SPEAKER_01: Where do the top medical authorities stand on standard care for a child with autism?
- 18:58SPEAKER_00: The established standard of care is clearly outlined by the Centers for Disease Control and Prevention.
- 19:03SPEAKER_00: The CDC groups autism treatments into several established categories.
- 19:07SPEAKER_01: These include behavioral, developmental, educational, social, and psychological approaches.
- 19:13SPEAKER_00: The main point the CDC emphasizes, based on decades of verifiable data, is that behavioral approaches currently have the most solid, established evidence for effectively treating autism symptoms and helping children build skills.
- 19:28SPEAKER_01: This leads us to a crucial non-negotiable rule for anyone listening.
- 19:32SPEAKER_01: Families must keep these evidence-based therapies firmly in place.
- 19:36SPEAKER_00: Any experimental cell treatment a family might consider exploring should only ever sit alongside standard care.
- 19:42SPEAKER_00: It must never replace it.
- 19:44SPEAKER_01: No one should ever stop a prescribed medication, abandon an educational program, or cancel a behavioral therapy session without consulting their own independent doctor.
- 19:54SPEAKER_00: That layered, cautious approach is the only medically responsible path forward.
- 19:59SPEAKER_00: The experimental intervention cannot oust the proven therapies.
- 20:02SPEAKER_00: You do not abandon the foundation of a house while you are testing out a new type of roof.
- 20:07SPEAKER_01: As we bring this deep dive to a close, let us review the complex journey we just took.
- 20:12SPEAKER_01: We started by looking at the intense lucrative marketing of paid packages offering umbilical cord blood and tissue cells.
- 20:19SPEAKER_00: We saw that the core motivation relies on a biological theory of calming brain inflammation.
- 20:26SPEAKER_00: But as we discussed, putting out the fire does not rebuild the drywall.
- 20:30SPEAKER_01: We examined the rigorous 2020 clinical trial of 180 children that used a double-blind placebo group, which ultimately found no overall benefit in social skills.
- 20:40SPEAKER_00: We explored the alarming reality of unknown long-term risks, short follow-up windows, and the tangible discovery of children's immune systems forming new antibodies against donor cells.
- 20:51SPEAKER_01: And we walked through the critical red flags, from clinics relying on emotional parent anecdotes to demanding fees for clinical trials.
- 20:59SPEAKER_01: The gap between the marketing promises of these clinics and the highly unresolved clinical evidence is vast.
- 21:10SPEAKER_00: Throughout all this research and data, you can see a very intense emotional friction playing out.
- 21:16SPEAKER_01: On one side, you have the necessary, methodical, often frustratingly slow pace of clinical science.
- 21:22SPEAKER_00: Science demands that we test every single batch of living cells, run massive double-blind placebo trials, wait years to understand long-term safety, and publish peer-reviewed data.
- 21:34SPEAKER_01: On the other side, you have the urgent, immediate timeline of a parent, a parent who is watching their child struggle today and just wants to do absolutely everything possible to help them reach their potential immediately.
- 21:46SPEAKER_00: That intense friction between slow science and urgent love is exactly where the commercial marketing thrives.
- 21:53SPEAKER_00: It is why holding on to the objective evidence is so incredibly difficult when you are in the thick of it, yet so profoundly essential for the safety of the child.
- 22:02SPEAKER_01: We started by talking about stepping away from the clean precision of an X ray and wading into the murky diagnostic waters of neurodevelopment.
- 22:10SPEAKER_00: Finding clarity in those muddy waters requires immense patience.
- 22:14SPEAKER_01: A willingness to ask hard questions, and a commitment to rigorous science, not just hopeful marketing.
- 22:20SPEAKER_01: Thank you for joining us on this deep dive.
- 22:22SPEAKER_01: We will see you on the next one.